Literature DB >> 27568729

Cannabinoids and Psychosis.

Deepak Cyril D'Souza1, Rajiv Radhakrishnan, Mohamed Sherif, Jose Cortes-Briones, John Cahill, Swapnil Gupta, Patrick D Skosnik, Mohini Ranganathan.   

Abstract

There is growing interest in the relationship between cannabis and psychosis. The link between cannabis use and psychosis comprises three distinct relationships: acute psychosis associated with cannabis intoxication, acute psychosis that lasts beyond the period of acute intoxication, and persistent psychosis not time-locked to exposure. Experimental studies reveal that cannabis, tetrahydrocannabinol (THC) and synthetic cannabinoids reliably produce transient positive, negative, and cognitive symptoms in healthy volunteers. Case-studies indicate that cannabinoids can induce acute psychosis which lasts beyond the period of acute intoxication and persisting as long as a month. Exposure to cannabis in adolescence is associated with an increased risk for later psychotic disorder in adulthood; this association is consistent, somewhat specific, shows a dose-response, and is biologically plausible. The link between cannabinoids and psychosis is greater with earlier age of exposure to cannabinoids, childhood abuse and genetic vulnerability. However, cannabinoids are neither necessary nor sufficient to cause a persistent psychotic disorder. More likely cannabinoids are a 'component cause' interacting with other known (family history) and unknown factors to result in psychosis outcomes. While more research is needed to better understand the relationship between cannabinoid use and psychosis, and the neural underpinnings of this link, clinicians should be mindful of the potential risk of psychosis especially in vulnerable populations, including adolescents and those with a psychosis diathesis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Cannabis; THC; cannabinoids; cognition; psychosis; schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27568729     DOI: 10.2174/1381612822666160826105628

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

Review 1.  Cannabis use among U.S. adolescents in the era of marijuana legalization: a review of changing use patterns, comorbidity, and health correlates.

Authors:  Christopher J Hammond; Aldorian Chaney; Brian Hendrickson; Pravesh Sharma
Journal:  Int Rev Psychiatry       Date:  2020-02-06

Review 2.  Combinatorial approaches for treating neuropsychiatric social impairment.

Authors:  Don Wei; Sherab Tsheringla; James C McPartland; A Z A Stephen Azariah Allsop
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2022-07-11       Impact factor: 6.671

3.  Differential Effect of Community Rehabilitation Reform on Hospitalizations of Patients with Chronic Psychotic Disorders With and Without Substance Use Disorder, Israel, 1991-2016.

Authors:  S Florentin; Y Neumark; S Raskin; T Bdolah-Abram; P Rosca
Journal:  Adm Policy Ment Health       Date:  2021-03

4.  Retrospective Review of Clozapine Use in Children and Adolescents.

Authors:  Ardelle Komaryk; Dean Elbe; Leah Burgess
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2021-02-01

Review 5.  Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.

Authors:  Marco Colizzi; Mirella Ruggeri; Sagnik Bhattacharyya
Journal:  Front Psychol       Date:  2020-05-14

Review 6.  Cannabis and Psychosis Through the Lens of DSM-5.

Authors:  Nathan T Pearson; James H Berry
Journal:  Int J Environ Res Public Health       Date:  2019-10-28       Impact factor: 3.390

Review 7.  Cannabinoids: from pot to lab.

Authors:  Esther Papaseit; Clara Pérez-Mañá; Ana Pilar Pérez-Acevedo; Olga Hladun; M Carmen Torres-Moreno; Robert Muga; Marta Torrens; Magí Farré
Journal:  Int J Med Sci       Date:  2018-08-06       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.